Nutriband Inc. (NASDAQ: NTRB) announced that it received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. This milestone moves the company closer to securing trademark protection for its product, which incorporates its AVERSA™ abuse-deterrent technology.
The Notice of Publication, dated September 2, means the trademarks will be published in the USPTO Trademark Official Gazette. If no objections are filed within the 30-day opposition period, the USPTO is expected to issue a Notice of Allowance, which would lead to registration. This process is standard for trademark protection but represents a significant step for Nutriband as it prepares to commercialize its fentanyl patch.
The fentanyl patch is designed to deter abuse and misuse and reduce the risk of accidental exposure to transdermal fentanyl, a powerful opioid. The AVERSA™ technology, which is incorporated into the patch, is protected by patents issued in 46 countries, providing a strong intellectual property foundation.
According to the company, the product has potential peak annual U.S. sales of $80 million to $200 million. This potential revenue underscores the importance of the product in addressing the opioid crisis while providing a significant market opportunity. The abuse-deterrent feature is critical, as fentanyl is highly potent and has been a major contributor to opioid-related overdoses.
The advancement of trademark protection is a key component of Nutriband's overall strategy to bring this product to market. Securing trademarks helps protect the brand and ensures that the product can be marketed without infringement issues. The company's focus on abuse-deterrent technology aligns with regulatory and public health priorities, potentially facilitating approval and adoption.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with its lead product being this abuse-deterrent fentanyl patch. The AVERSA™ technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This versatility could lead to additional products in the future.
The company's website is www.nutriband.com, and more information about Nutriband is available in its newsroom at https://ibn.fm/NTRB. The full press release can be viewed at https://ibn.fm/p1wVE.
This development is important because it signals progress in the commercialization of a product that could have a substantial impact on public health. By deterring abuse of fentanyl, the patch could help reduce opioid-related deaths and provide a safer option for patients requiring pain management. The potential market size indicates strong commercial viability, which could attract investors and partners.
As Nutriband moves forward, the trademark publication is a procedural but necessary step. The company must now await the opposition period to conclude. If successful, it will receive a Notice of Allowance, bringing it one step closer to full trademark registration.
Overall, this news highlights Nutriband's commitment to addressing the opioid epidemic through innovation. The combination of strong intellectual property, a clear regulatory path, and significant market potential positions the company to make a meaningful difference in pain management while delivering value to shareholders.
